Login to Your Account

Phase III Protocol Cleared for Grass Vaccine

Allergy Therapeutics Stock Surges as FDA Lifts Hold

By Cormac Sheridan
Staff Writer

Monday, August 6, 2012
Shares in Allergy Therapeutics plc surged 36 percent Friday on news that the FDA had finally lifted a five-year clinical hold on the development of its Monophosphoryl Lipid A (MPL)-adjuvanted grass pollen allergy vaccine (Grass MATA MPL/ Pollinex Quattro Grass 0.5ml) and had cleared a Phase III protocol for determining the product's efficacy.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription